Full Press Release Details
Altimmune Completes Enrollment in Phase 1b Clinical Trial of NasoShield, a Single Dose Intranasal Anthrax Vaccine Candidate.
ALT
Altimmune Completes Enrollment in Phase 1b Clinical Trial of NasoShield, a Single Dose Intranasal Anthrax Vaccine Candidate
Key Takeaway: Altimmune Completes Enrollment in Phase 1b Clinical Trial of NasoShield, a Single Dose Intranasal Anthrax Vaccine Candidate